Elena Trabacchi

Piacenza, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population.

Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population.

Journal: Hematological oncology
Published: February 14, 2025

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.

Journal: Haematologica
Published: October 13, 2021

Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.

Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.

Journal: Targeted oncology
Published: July 20, 2021

Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.

Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.

Journal: Annals of hematology
Published: September 06, 2019

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.

Journal: Blood advances
Published: August 20, 2019

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Journal: Cancer
Published: October 30, 2017

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

Journal: American journal of hematology
Published: August 10, 2016

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

Journal: Haematologica
Published: February 23, 2016

Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis.

Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: January 31, 2016

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.

Journal: Haematologica
Published: April 27, 2015

Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens.

Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens.

Journal: Blood transfusion = Trasfusione del sangue
Published: August 07, 2014

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.

Journal: American journal of hematology
Published: September 11, 2013
Showing 1-12 of 13

Last Updated: 09/26/2026